Literature DB >> 7158331

Aspergillus pneumonia in chronic granulomatous disease: recurrence and long-term outcome.

D S Chudwin, D W Wara, M J Cowan, A J Ammann.   

Abstract

Four of 13 patients followed with chronic granulomatous disease (CGD) developed biopsy-proven Aspergillus pneumonia. Two patients died of disseminated aspergillosis despite intensive treatment; delays in diagnosis appear to have been a major contributing cause. Two patients survived two episodes each of Aspergillus pneumonia, three and six years apart. At 12 and 18 years of age, both are well and active, although their chest X-rays show residual scarring and pulmonary function tests indicate obstructive lung disease. These cases demonstrate that in patients with CGD, 1) multiple episodes of Aspergillus pneumonia can occur; 2) effective immunity to the organism does not develop after infection; and 3) some survivors of Aspergillus pneumonia experience only minimal morbidity.

Entities:  

Mesh:

Year:  1982        PMID: 7158331     DOI: 10.1111/j.1651-2227.1982.tb09548.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  4 in total

Review 1.  Aspergillosis.

Authors:  G P Bodey; S Vartivarian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

2.  Pulmonary Aspergillus chest wall involvement in chronic granulomatous disease: CT and MRI findings.

Authors:  A Kawashima; J E Kuhlman; E K Fishman; C M Tempany; D Magid; H M Lederman; J A Winkelstein; E A Zerhouni
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

3.  Chronic granulomatous disease: a review of the infectious and inflammatory complications.

Authors:  Eunkyung Song; Gayatri Bala Jaishankar; Hana Saleh; Warit Jithpratuck; Ryan Sahni; Guha Krishnaswamy
Journal:  Clin Mol Allergy       Date:  2011-05-31

4.  Invasive Aspergillus infections in hospitalized patients with chronic lung disease.

Authors:  Mireya Wessolossky; Verna L Welch; Ajanta Sen; Tara M Babu; David R Luke
Journal:  Infect Drug Resist       Date:  2013-05-27       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.